Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 512345

Auris Medical Fails Again in Phase III Trial

Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.

Read More »

Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after the company’s lead drug began Phase I testing, San Diego-based Crinetics Pharmaceuticals Inc. secured $63.5 million in Series B financing.

Read More »

FDA Accepts for Filing Supplemental Biologics License Application for Xeomin in Adult Patients with Sialorrhea

Merz North America announced today that the U.S. Food and Drug Administration accepted for filing a supplemental Biologics License Application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients.

Read More »

U.S. health spending twice other countries’ with worse results

The U.S. spends about twice what other high-income nations do on health care but has the lowest life expectancy and the highest infant mortality rates, a new study suggests.

Read More »

Teva rebuffs EU pay-for-delay charge at hearing

Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter’s sleep disorder drug at a hearing.

Read More »

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.

Read More »

Are Life Science Companies Falling Behind Tech Companies?

Tech companies, such as Google, Apple, Facebook, Amazon and others, have been making significant forays into the life sciences. Although many have praised the ambitions, innovation and deep pockets these companies bring to the industry, a new report by global consulting and advisory company EY suggests that life science companies are in danger of falling behind their tech brethren.

Read More »

3 Ways Event Marketing Betters Your Healthcare Brand

When popular retailers launch new products, they do not have to do much promotion to capture people’s interest. Consumers are so eager to nab their goods, they will buy out their inventories in days, and sometimes minutes. Healthcare “products,” on the other hand, rarely hold the same appeal.

Read More »

Proteostasis Therapeutics Snags Breakthrough Designation

The U.S. Food and Drug Administration granted Cambridge, Mass.-based Proteostasis Therapeutics‘ investigational cystic fibrosis add-on therapy Breakthrough Therapy Designation.

Read More »

Keytruda Granted Priority Review for Cervical Cancer

The U.S. FDA accepted Merck & Company’s supplemental Biologics License Application and granted Priority Review for Keytruda (pembrolizumab) in advanced cervical cancer.

Read More »

W2O Reports 16th Consecutive Year of Double-Digit Annual Revenue Growth in 2017

W2O, an integrated network of complementary analytics-driven firms, reported another year of double-digit revenue growth with a 17.6 percent increase in revenue to $144.3 million in 2017.

Read More »

UnitedHealth names Andrew Witty as Optum head

UnitedHealth Group named its board member and former GlaxoSmithKline head Andrew Witty as chief executive of the health insurer’s pharmacy benefit unit Optum, effective July 1, 2018.

Read More »

FDA Halts Advaxis Study Following Patient Death

Shares of Advaxis Inc. were down more than 21 percent in after the company announced that the U.S. FDA halted a Phase I/II trial that uses an AstraZeneca Pharmaceuticals LP drug following the death of a patient.

Read More »

Roche CEO says new drugs will offset biosimilar incursions

Swiss drugmaker Roche expects to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals’ copies through its new medicines.

Read More »

Newer gout drug poses risk to heart patients

Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.

Read More »

Biogen Buys Schizophrenia Asset from Pfizer

Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.

Read More »

Improved Pressure-ulcer Outcomes with Wearable Technology

In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?

Read More »

Realm Therapeutics Conjunctivitis Drug Fails Phase II Trial

Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.

Read More »

Impax faces U.S. antitrust trial over generic’s delay

Impax Laboratories Inc. went to trial over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.

Read More »

Anthera’s lead drug fails study, shares slump

Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.

Read More »

Page 2 of 512345

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation